ESC Premium Access

Impact of alirocumab on Lp(a) in individuals with and without moderate CKD

Congress Presentation

About the speaker

Professor Peter Toth

CGH Medical Center and The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore (United States of America)
5 presentations
0 follower

6 more presentations in this session

Inhibition of lipopolysaccharide induced gene expression by HDL from healthy subjects and patients with acute myocardial infarction

Speaker: Assistant Professor S. Imaizumi (Fukuoka, JP)

Thumbnail

Association of the postprandial chylomicron triglyceride/apoB index and cardiovascular events

Speaker: Doctor C. Werner (Homburg, DE)

Thumbnail

Malondialdehyde assay in evaluation of aspirin antiplatelet effects

Speaker: Mrs L. Dannenberg (Duesseldorf, DE)

Thumbnail

C2238 atrial natriuretic peptide molecular variant determines an increased platelet aggregation through the activation of NOX2 and the reduction of cAMP

Speaker: Assistant Professor S. Sciarretta (Rome, IT)

Thumbnail

Efficacy and safety of alirocumab in patients with multiple manifestations of cardiovascular disease (CVD): a post-hoc analysis of ODYSSEY program

Speaker: Professor K. Ray (London, GB)

Thumbnail

Access the full session

Lipids and platelets

Speakers: Professor P. Toth, Assistant Professor S. Imaizumi, Doctor C. Werner, Mrs L. Dannenberg, Assistant Professor S. Sciarretta...
Thumbnail

About the event

Image

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb